Advertisement
UK markets closed
  • NIKKEI 225

    38,102.44
    -712.12 (-1.83%)
     
  • HANG SENG

    17,936.12
    -5.66 (-0.03%)
     
  • CRUDE OIL

    79.57
    +1.12 (+1.43%)
     
  • GOLD FUTURES

    2,330.50
    -18.60 (-0.79%)
     
  • DOW

    38,693.04
    +103.88 (+0.27%)
     
  • Bitcoin GBP

    51,715.60
    -746.57 (-1.42%)
     
  • CMC Crypto 200

    1,370.02
    -18.14 (-1.31%)
     
  • NASDAQ Composite

    17,771.83
    +82.95 (+0.47%)
     
  • UK FTSE All Share

    4,437.53
    -0.84 (-0.02%)
     

Guardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval.

Guardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval.

Shares of Guardant Health were rising sharply after the cancer company said a Food and Drug Administration advisory committee recommended the agency approve the company’s blood test for colorectal cancer screening. The test, Shield, is for people 45 and older who are at average risk for the disease, according to the release. “The recommendation signals the advisory committee panel’s consensus on Shield’s safety and effectiveness with its proposed intended use, and their conclusion that its benefits as a primary non-invasive screening option outweigh any potential risks,” according to the release.